Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.9188
−$0.0535 · -5.50%
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Regular session
$0.9188
−$0.0535 · -5.50%
Regular session · ET · Market data may be delayed.
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Day range
Current $0.9188
52-week range
Current $0.9188
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
41
Mixed
Risk
78
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Day range
Current $0.9188
52-week range
Current $0.9188
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cost of goods sold | — | — | — | 1.27K USD |
| Gross profit | — | — | — | −1.27K USD |
| Research and development | 4.1M USD | 4.21M USD | 4.08M USD | 392.86K USD |
| Selling, general, and administrative | 9.35M USD | 6.75M USD | 3.55M USD | 2.31M USD |
| Operating expenses | 13.46M USD | 10.96M USD | 7.63M USD | 2.7M USD |
| Interest income | 223.82K USD | 309.25K USD | 249.09K USD | — |
| Interest expense | — | — | 17.1K USD | 107.11K USD |
| Depreciation and amortization | 6.87K USD | 1.88K USD | 1.98K USD | 1.27K USD |
| Operating income | −13.46M USD | −10.96M USD | −7.63M USD | −2.7M USD |
| Net income | −13.24M USD | −10.65M USD | −8.36M USD | −6.71M USD |
Company facts updated Oct 8, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$32.00
3382.80% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 20, 2024 | 1:15 | — | — |
Effective Aug 20, 2024
1:15
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
Dimensional - US Sustainability Core 1 ETFDFSUAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
